| Aug 23 |
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
|
| Aug 22 |
ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares
|
| Aug 20 |
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
|
| Aug 20 |
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
|
| Aug 19 |
Looking Into ARS Pharmaceuticals's Recent Short Interest
|
| Aug 15 |
Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)
|
| Aug 13 |
Raymond James ups ARS to strong buy, cites FDA neffy approval
|
| Aug 12 |
ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call Transcript
|
| Aug 12 |
ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call
|
| Aug 12 |
ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval
|
